United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M

UNITED THERAPEUTICS Corp

2024-Q1 EPS reported $6.17 revenue$677,700,000

Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.
Net income $306.6M ($6.17 diluted EPS) vs $240.9M ($4.86 EPS) in Q1 2023.
Implemented $1B accelerated share repurchase with Citi; initial delivery of 3.275M shares.
Tyvaso DPI sales $227.5M (+92% YoY); nebulized Tyvaso $145.0M (+21%).
Revenue growth driven by increased patient utilization and Part D redesign tailwinds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.